Technetium (99mTc) sestamibi

Technetium (^99mTc) sestamibi
Clinical data
Trade names	Cardiolite
License data	US FDA: TECHNETIUM_TC-99M_SESTAMIBI_KIT;
Routes of; administration	Intravenous
ATC code	V09GA01 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	NA
Protein binding	1%
Metabolism	Nil
Elimination half-life	Variable
Excretion	Fecal (33%) and renal (27%)
Identifiers
	IUPAC name Hexakis(2-methoxy-2-methylpropylisonitrile); technetium (99mTc);
CAS Number	109581-73-9 ;
PubChem CID	5384;
ChemSpider	396214;
UNII	971Z4W1S09;
KEGG	D01060;
ChEBI	CHEBI:9423;
CompTox Dashboard (EPA)	DTXSID00911248 ;
Chemical and physical data
Formula	C36H66N6O6Tc
Molar mass	777 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [99Tc-5](C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)(C#[N+]CC(C)(C)OC)C#[N+]CC(C)(C)OC;
	(verify)

Technetium (^99mTc) sestamibi (INN; commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".

Sestamibi is taken up by tissues with large numbers of mitochondria and negative plasma membrane potentials. Sestamibi is mainly used to image the myocardium (heart muscle). It is also used in the work-up of primary hyperparathyroidism to identify parathyroid adenomas, for radioguided surgery of the parathyroid and in the work-up of possible breast cancer.